A phase II study of photodynamic therapy (PDT) using 2-[1-Hexyloxyethyl]-2 devinyl pyropheophorbide-a (HPPH) for treatment of advanced obstructing endobronchial lung cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HPPH (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2014 Biomarkers information updated
- 18 Sep 2012 Planned end date changed from 1 Nov 2010 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned number of patients changed from 20 to 6 as reported by ClinicalTrials.gov.